U.S. flag An official website of the United States government
  1. Home
  2. About FDA
  3. Performance Data
  4. FDA-TRACK: Agency-wide Program Performance
  5. FDA-TRACK: Prescription Drug User Fee Act Historical Performance - Procedural Notifications and Responses
  1. FDA-TRACK: Agency-wide Program Performance

FDA-TRACK: Prescription Drug User Fee Act Historical Performance - Procedural Notifications and Responses

Prescription Drug Applications and Supplements

Procedural Notifications and Responses

Meeting
Management

The Federal Food, Drug, and Cosmetic Act (the FD&C Act), as amended by the Prescription Drug User Fee Act of 2022 (PDUFA VII), authorizes FDA to assess and collect fees for prescription drug products from October 2023 through September 2027. FDA dedicates these fees toward expediting the drug development process and the process for the review of human drug applications, including postmarket drug safety activities.

Download PDUFA Historical Performance: Procedural Notifications and Responses Dataset


Footnotes:

  • * Performance is currently preliminary due to pending submissions.
  • ** New Performance Goal for PDUFA VII with performance tracking beginning in FY23 (see Changes for this Goal, page 35 for Human Factors Protocol to INDs and pages 12-13 for Priority and Standard NME NDA and Original BLA PMRs).
  •  

 

 

Sign up to receive FDA-TRACK updates

Get regular FDA email updates delivered on this topic to your inbox.

Back to Top